AR078224A1 - Composicon para el tratamiento del cancer de prostata - Google Patents

Composicon para el tratamiento del cancer de prostata

Info

Publication number
AR078224A1
AR078224A1 ARP100101489A ARP100101489A AR078224A1 AR 078224 A1 AR078224 A1 AR 078224A1 AR P100101489 A ARP100101489 A AR P100101489A AR P100101489 A ARP100101489 A AR P100101489A AR 078224 A1 AR078224 A1 AR 078224A1
Authority
AR
Argentina
Prior art keywords
degarelix
solvent
composition
treatment
prostate cancer
Prior art date
Application number
ARP100101489A
Other languages
English (en)
Inventor
Lars Erichsen
Per Cantor
Tine Kold Olesen
Original Assignee
Ferring Int Ct Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41066059&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR078224(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Int Ct Sa filed Critical Ferring Int Ct Sa
Publication of AR078224A1 publication Critical patent/AR078224A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Reivindicacion 1: Una composicion que comprende degarelix o una sal farmacéuticamente aceptable del mismo para el tratamiento del cáncer de prostata, en donde la composicion comprende un liofilisato de degarelix y un excipiente disuelto en un solvente, y es administrada a un paciente en una dosis inicial de entre 200 y 300 mg de degarelix a una concentracion de entre 20 y 80 mg de degarelix por mL de solvente; seguido 14 - 56 días luego de la dosis inicial por una dosis de mantenimiento de entre 320 y 550 mg de degarelix a una concentracion de entre 50 y 80 mg de degarelix por mL de solvente; (opcionalmente) seguido por una o más dosis adicionales de mantenimiento(s) de entre 320 y 550 mg de degarelix a una concentracion de entre 50 y 80 mg de degarelix por mL de solvente administrada con un intervalo de 56 días a 112 días entre cada dosis de mantenimiento.
ARP100101489A 2009-05-01 2010-04-30 Composicon para el tratamiento del cancer de prostata AR078224A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09251242 2009-05-01
US18781909P 2009-06-17 2009-06-17

Publications (1)

Publication Number Publication Date
AR078224A1 true AR078224A1 (es) 2011-10-26

Family

ID=41066059

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101489A AR078224A1 (es) 2009-05-01 2010-04-30 Composicon para el tratamiento del cancer de prostata

Country Status (18)

Country Link
US (1) US8722088B2 (es)
EP (1) EP2424503B1 (es)
JP (5) JP5973909B2 (es)
KR (1) KR101795643B1 (es)
CN (2) CN105663059A (es)
AR (1) AR078224A1 (es)
AU (1) AU2010243273B2 (es)
BR (1) BRPI1010874A8 (es)
CA (1) CA2759888A1 (es)
ES (1) ES2641767T3 (es)
IL (1) IL215772A (es)
MX (1) MX2011011431A (es)
NZ (1) NZ595767A (es)
RU (1) RU2536245C2 (es)
SA (1) SA110310340B1 (es)
TW (2) TWI508734B (es)
WO (1) WO2010125468A1 (es)
ZA (1) ZA201107879B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
EP2424503B1 (en) 2009-05-01 2017-07-05 Ferring BV Composition for the treatment of prostate cancer
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
DK3564357T3 (da) 2010-02-01 2022-06-20 Rebiotix Inc Bakterieterapi mod clostridium difficile colitis
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
ES2617336T3 (es) 2010-10-27 2017-06-16 Ferring B.V. Procedimiento para la fabricación de degarelix y sus productos intermedios
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
CN102204889B (zh) * 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
MY182320A (en) * 2012-06-01 2021-01-19 Ferring Bv Downstream process
TWI571254B (zh) * 2016-01-08 2017-02-21 誠熱實業股份有限公司 放射治療用之醫療輔助裝置
CN105769774A (zh) * 2016-03-02 2016-07-20 张光泉 一种注射用醋酸地加瑞克冻干组合物及其制备方法
US10933134B2 (en) * 2017-03-16 2021-03-02 Memorial Sloan Kettering Cancer Center Combination therapies for treatment of cancer
RU2731002C1 (ru) * 2019-10-22 2020-08-26 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения рака предстательной железы

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP0002749B2 (en) 1977-12-26 1987-08-12 IHARA CHEMICAL INDUSTRY Co., Ltd. Process for producing aromatic monocarboxylic acid
EP0593491B1 (en) 1991-04-25 1996-10-23 DEGHENGHI, Romano Luteinizing hormone releasing hormone antagonist peptides
ES2159516T5 (es) 1992-02-12 2005-05-01 Daikyo Gomu Seiko Ltd. Un instrumento medico.
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5506207A (en) 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5821230A (en) 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US5925730A (en) 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
FR2776520B1 (fr) 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
ATE357261T1 (de) * 2001-07-11 2007-04-15 Sca Hygiene Prod Ab Kupplung von cyclooligosacchariden zu polysacchariden
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
US7098305B2 (en) * 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
CN1411803A (zh) 2002-08-29 2003-04-23 四川大学 制备前体脂质体的方法及其装置
US7884071B2 (en) * 2002-09-27 2011-02-08 Zentaris Gmbh Administration form for pharmaceutically active peptides with sustained release and method for the production thereof
AR042815A1 (es) 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2007130809A2 (en) 2006-05-06 2007-11-15 Volodymyr Brodskyy An automatic injectable drug mixing device
EP1891964A1 (en) 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
IL182922A0 (en) 2007-05-02 2007-09-20 Medimop Medical Projects Ltd Automatic liquid drug reconstitution apparatus
ES2589322T3 (es) 2008-02-11 2016-11-11 Safety Syringes, Inc. Jeringa con protector de seguridad de aguja y clip para evitar la liberación del protector durante un proceso de reconstitución
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
EP2424503B1 (en) * 2009-05-01 2017-07-05 Ferring BV Composition for the treatment of prostate cancer
TW201043221A (en) 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
ES2617336T3 (es) 2010-10-27 2017-06-16 Ferring B.V. Procedimiento para la fabricación de degarelix y sus productos intermedios
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
EP2731607B1 (en) 2011-07-15 2017-10-11 Ferring B.V. Method for timing a colonoscopy wherein a picosulate composition is administered

Also Published As

Publication number Publication date
CN105663059A (zh) 2016-06-15
JP2023093643A (ja) 2023-07-04
TWI583391B (zh) 2017-05-21
RU2536245C2 (ru) 2014-12-20
TW201039840A (en) 2010-11-16
AU2010243273B2 (en) 2016-06-16
US8722088B2 (en) 2014-05-13
JP2012525373A (ja) 2012-10-22
JP2022088517A (ja) 2022-06-14
JP5973909B2 (ja) 2016-08-23
RU2011142843A (ru) 2013-06-10
KR101795643B1 (ko) 2017-11-09
JP7297116B2 (ja) 2023-06-23
JP2020183444A (ja) 2020-11-12
SA110310340B1 (ar) 2015-02-04
EP2424503A1 (en) 2012-03-07
TWI508734B (zh) 2015-11-21
IL215772A (en) 2016-10-31
JP6462447B2 (ja) 2019-01-30
ZA201107879B (en) 2012-07-25
TW201600106A (zh) 2016-01-01
WO2010125468A1 (en) 2010-11-04
BRPI1010874A8 (pt) 2018-01-02
CA2759888A1 (en) 2010-11-04
AU2010243273A1 (en) 2011-11-10
BRPI1010874A2 (pt) 2017-05-30
JP7296922B2 (ja) 2023-06-23
ES2641767T3 (es) 2017-11-13
EP2424503B1 (en) 2017-07-05
NZ595767A (en) 2012-12-21
US20100305042A1 (en) 2010-12-02
KR20120015310A (ko) 2012-02-21
JP2015157818A (ja) 2015-09-03
MX2011011431A (es) 2012-02-23
CN102421414A (zh) 2012-04-18
IL215772A0 (en) 2012-01-31

Similar Documents

Publication Publication Date Title
AR078224A1 (es) Composicon para el tratamiento del cancer de prostata
CO6160321A2 (es) Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo
ES2526648T3 (es) Método para mejorar el estrés oxidativo y la memoria de trabajo mediante la administración de pterostilbeno
AR081254A1 (es) Composicion farmaceutica que comprende ave0010 e insulina glargina
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
CY1114215T1 (el) Φαρμακευτικες συνθεσεις διαλυματος για υπο πιεση εισπνευστηρες μετρουμενης δοσης
PE20170302A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
AR081439A1 (es) Composicion para el tratamiento de la hiperplasia prostatica benigna de prostata
CO6150188A2 (es) Uso de teencteplasa para tratar un ictus isquemico agudo
CO6640268A2 (es) Formas de decodificación oral de bendamustina y su uso terapéutico
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
AR086356A1 (es) Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2
AR082803A1 (es) Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p
CO6280574A2 (es) Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia
AR062659A1 (es) Composicion de liberacion sostenida de levodopa y metodo para su uso
AR080096A1 (es) Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib
CL2021003034A1 (es) Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
CL2016002318A1 (es) Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits.
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
ECSP077843A (es) Tratamiento o prevención del prurito
PE20130782A1 (es) Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.

Legal Events

Date Code Title Description
FC Refusal